Westover Capital Advisors LLC raised its position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 17.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,966 shares of the company’s stock after purchasing an additional 726 shares during the period. Westover Capital Advisors LLC’s holdings in Medpace were worth $1,522,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently modified their holdings of the company. Contravisory Investment Management Inc. acquired a new position in shares of Medpace in the 4th quarter valued at $26,000. RiverPark Advisors LLC acquired a new position in shares of Medpace in the 4th quarter valued at $26,000. GAMMA Investing LLC acquired a new position in shares of Medpace in the 4th quarter valued at $30,000. McGlone Suttner Wealth Management Inc. purchased a new position in Medpace during the 4th quarter worth $33,000. Finally, FinTrust Capital Advisors LLC purchased a new position in Medpace during the 3rd quarter worth $30,000. 77.98% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at Medpace
In other Medpace news, CEO August J. Troendle sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now directly owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Medpace news, CEO August J. Troendle sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the sale, the chief executive officer now directly owns 4,833,019 shares of the company’s stock, valued at approximately $1,995,940,186.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO August J. Troendle sold 25,000 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $408.71, for a total transaction of $10,217,750.00. Following the sale, the chief executive officer now directly owns 4,733,019 shares in the company, valued at $1,934,432,195.49. The disclosure for this sale can be found here. In the last three months, insiders sold 204,442 shares of company stock worth $82,702,867. 20.30% of the stock is owned by corporate insiders.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on Medpace
Medpace Stock Performance
NASDAQ:MEDP traded down $4.21 during mid-day trading on Thursday, hitting $393.65. 127,721 shares of the company’s stock traded hands, compared to its average volume of 249,571. The firm’s 50 day simple moving average is $398.32 and its 200 day simple moving average is $328.94. Medpace Holdings, Inc. has a 1 year low of $197.39 and a 1 year high of $421.00. The company has a market cap of $12.20 billion, a PE ratio of 40.79, a price-to-earnings-growth ratio of 1.93 and a beta of 1.40.
Medpace (NASDAQ:MEDP – Get Free Report) last posted its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, beating the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The firm had revenue of $511.00 million during the quarter, compared to the consensus estimate of $512.39 million. During the same period last year, the firm posted $2.27 EPS. The firm’s revenue for the quarter was up 17.7% on a year-over-year basis. On average, research analysts expect that Medpace Holdings, Inc. will post 11.23 earnings per share for the current fiscal year.
About Medpace
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Read More
- Five stocks we like better than Medpace
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Meta Stock: 3 Reasons This Stumble Is a Golden Buying Opportunity
- Find and Profitably Trade Stocks at 52-Week Lows
- 3 Staples Stocks to Cushion Lower Consumer Sentiment
- The 3 Best Blue-Chip Stocks to Buy Now
- Zillow’s Earnings Dip: An Opportunity for Visionaries
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.